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  EVIDENCE-BASED ANSWER 
Treatment of otitis media with effusion (OME) with nasal steroids is not recommended (strength of 
recommendation [SOR]=A, based on systematic review). 
Limited evidence exists that shows nasal steroids may increase the rate of resolution of OME in the short term, 
alone or in combination with antibiotics (SOR: A, based on randomized controlled trials). However, within 3 to 
12 weeks, resolution of OME with nasal steroids is no better than placebo. No evidence exists that treatment 
with nasal steroids has any effect on decreasing potential complications of OME, such as hearing loss and 
delayed language development. 
  EVIDENCE SUMMARY 
OME is diagnosed by visualization of an effusion on otoscopy, by limited tympanic membrane movement on 
insufflation, or by abnormal tympanometry, all in the absence of acute inflammation. OME is defined as chronic 
when the effusion has been present for at least 3 months. 
The natural course of OME was observed in a longitudinal cohort study of 1439 children aged 2 years in the 
Netherlands. Single or recurrent flat screening tympanograms were noted in 20% and remitted spontaneously 
at a rate of 50% every 3 months.1 This prevalence and spontaneous resolution rate is consistent with other 
studies. 
Three randomized controlled trials published in English tested intranasal steroids for OME (Table). 
The Lilholdt study enrolled children through a private ear, nose, and throat clinic over autumn, winter, and 
spring with a primary or new bout of OME. 
The Shapiro study enrolled children who had documented allergic rhinitis and OME with failure to respond to 4 
weeks of oral antihistamine and decongestant therapy at time of entry. This was the only study with short-term 
follow-up comparing intranasal steroids with control. The odds ratio for OME persisting after 3 weeks was 2.12 
(95% confidence interval [CI], 0.65-6.90).3 
The Tracy study enrolled children with chronic OME referred to a chronic ear clinic from October to June. 
Inclusion criteria included 3 episodes of acute otitis media in the prior 6 months or 4 episodes in the prior 12 
months. This was a randomized comparison study with 3 treatment arms: an active nasal spray group and 2 
control groups. The odds ratio for OME persisting after short-term follow-up was 0.79 (95% CI, 0.20-3.19); after 
intermediate follow-up the odds ratio was 0.72 (95% CI, 0.21-2.44). 
This study, which included a symptom score after 3 months, favored treatment, with a weighted mean 
difference of -4.5, but with wide 95% CI of -10.28 to 1.28. An effect was demonstrated on clearing effusions in 
the short term, but the advantage appeared to vanish for the most part by 3 months. The study did not evaluate 
improvements in hearing.4 
No adverse effects of intranasal steroid treatment were seen except for transient drops in cortisol levels in the 
Shapiro study, which tested dexamethasone. Approximately 8 randomized controlled trials using oral steroids 
with and without antibiotics for OME and chronic OME mirror a trend for short-term benefit of treatment, 
spontaneous resolution, and frequent recurrence. 
In summary, limited evidence exists for short-term improvement of OME with intranasal steroids plus 
antibiotics, and no evidence exists for lasting beneficial effect on effusion or OME associated hearing loss. 
 
TABLE  
Clinical trials: Intranasal steroids for otitis media with effusion 
Study Subjects Groups Duration Outcome 
Lilholdt 
1982 
n=70 
(aged 4-14 
yrs with 
OME) 
Beclomethasone vs 
placebo 
2 mo No benefit at end of 
treatment month or after 
second month with no 
treatment by otoscopy, 
tympanometry, or 
audiometry. 
Spontaneous improvement 
in 25% and resolution in 
25%.1 
Shapiro 
1982 
n=45 Dexamethasone vs 
placebo 
3 wk 
(aged 2-
12 yrs 
with OME 
>1 mo) 
Normalization of ear 
pressure and middle ear 
gradient at 1 and 2 weeks 
of treatment group over 
placebo (P<.05). 
No significant differences 
by third week.2 
Tracy 
1998 
n=61 
(aged 3-11 
yrs with 
chronic 
OME) 
Beclomethasone + 
amoxicillin vs 
placebo + 
amoxicillin vs 
amoxicillin alone 
12 wk Beclomethasone group 
showed a significantly 
greater frequency of 
resolution of chronic 
effusion at 4 and 8 weeks 
(P<.05) but not at 12 
weeks, with improved 
middle ear pressures: left 
(P=.004) and right (P=.010) 
over the 12 weeks.3 
OME, otitis media with effusion 
  RECOMMENDATIONS FROM OTHERS 
The Canadian Task Force on Preventative Health Care found insufficient evidence to recommend screening 
for OME to prevent delayed language development.5 
The Cochrane Ear, Nose and Throat Disorders Group concludes that both oral and topical intranasal steroids 
alone or in combination with an antibiotic lead to a quicker resolution of OME in the short term, but no long-
term benefit is seen from treating OME effusions or associated hearing loss with topical intranasal steroids.6 
They separately reviewed antibiotic treatment for OME, noting the short-term benefit above, but cited several 
drawbacks including cost and increased antibacterial resistance.7 
The American Academy of Family Physicians Clinical Recommendation on Otitis Media with Effusion in Young 
Children does not recommend steroid medications for treatment of OME in a child of any age.8 
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Management of OME can be challenging and expensive—annual costs are estimated at 
$5 billion. Antibiotics are often inappropriately prescribed for OME, which may promote 
bacterial resistance. Commonly, clinicians augment OME treatment with antihistamines, 
decongestants, and steroids. Yet studies such as those cited above confirm that these 
treatments offer limited or no benefit. We must avoid the kitchen-sink treatment of OME. 
Furthermore, randomized controlled trials have shown that 80% to 90% of cases of acute 
otitis media and OME resolve without any therapy. 
However, children with chronic OME, especially those with bilateral disease or possible 
hearing loss, may benefit from tympanostomy tube placement and adenoidectomy. If the 
OME doesn’t clear within 3 months, refer to an ear, nose, and throat specialist. 
Prevention efforts are valuable. Immunization of infants with pneumococcal conjugate 
vaccine reduced tympanostomy tube placement by 20% to 39%.9,10 Since increased 
incidence of OME and recurrent acute otitis media are associated with secondhand smoke 
exposure, motivating parents to quit smoking may further reduce chronic OME. 
·  A C K N O W L E D G M E N T S  ·  
Thanks to Marianne Broers, MD for her translation of reference 1 from Dutch. 
R E F E R E N C E S  
1. Zielhuis  GA, Schilder  A, van den Broek  P. The spontaneous course of otitis media 
with effusion in young children [in Dutch].  Ned Tijdschr Geneeskd 1991;135:1754–
1757. 
2. Lildholdt  T, Kortholm  B. Beclomethasone nasal spray in the treatment of middle-
ear effusion—a double-blind study.  Int J Pediatr Otorhinolaryngol 1982;4:133–137. 
3. Shapiro  GG, Bierman  CW, Furukawa  CT , et al.  Treatment of persistent 
eustachian tube dysfunction in children with aerosolized nasal dexamethasone 
phosphate versus placebo.  Ann Allergy 1982;49:81–85. 
4. Tracy  JM, Demain  JG, Hoffman  KM, Goetz  DW. Intranasal beclomethasone as 
an adjunct to treatment of chronic middle ear effusion.  Ann Allergy Asthma 
Immunol 1998;80:198–206. 
5. Butler  CC, MacMillan  HL. Early detection of OME in the first four years of life to 
prevent delayed language development. Systematic Review & Recommendations. 
CTF-PHC Technical Report #01-3. September 2000.  London, Ont: Canadian Task 
Force; 2000. Available at: http://www.ctfphc.org, or by request from the task force 
office ctf@ctfphc.org. Accessed on July 10, 2003. 
6. Butler  CC, Van Der Voort   JH. Oral or topical nasal steroids for hearing loss 
associated with otitis media with effusion in children.  Cochrane Database Syst 
Rev 2002;(4):CD001935. 
7. Van Balen   FAM, Canekin  II LJ, Williamson  IG. Antibiotic treatment for otitis media 
with effusion in children aged 6 months-12 years (Protocol for a Cochrane Review). 
 In: The Cochrane Library, Issue 1, 2003. Oxford: Update Software. 
8. American Academy of Family Physicians.  Otitis Media with Effusion in Young 
Children. AAFP Clinical Recommendations, Part II—Clinical Policies.  Leawood, 
Kansas: American Academy of Family Physicians; 1994 (reaffirmed 2000, 2001). 
Available at: http://www.aafp.org/x1596.xml. Accessed on June 30, 2003. 
9. Black  S, Shinefield  H, Fireman  B , et al.  Efficacy, safety and immunogenicity of 
heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser 
Permanente Vaccine Study Center Group.  Pediatr Infect Dis J 2000;19:187–195. 
10. Eskola  J, Kilpi  T, Palmu  A , et al.  Efficacy of a pneumococcal conjugate vaccine 
against acute otitis media.  N Engl J Med 2001;344:403–409. 
 
